Search

Your search keyword '"Piper‐Vallillo, Andrew J."' showing total 16 results
Start Over Author "Piper‐Vallillo, Andrew J."
16 results on '"Piper‐Vallillo, Andrew J."'

2. A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Author

Viray, Hollis, primary, Piper-Vallillo, Andrew J., additional, Widick, Page, additional, Academia, Emmeline, additional, Shea, Meghan, additional, Rangachari, Deepa, additional, VanderLaan, Paul A., additional, Kobayashi, Susumu S., additional, and Costa, Daniel B., additional

Published
2024
Full Text
View/download PDF

3. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.

Author

Chang, Allison E B, Piper-Vallillo, Andrew J, Mak, Raymond H, Lanuti, Michael, Muzikansky, Alona, Rotow, Julia, Jänne, Pasi A, Mino-Kenudson, Mari, Swanson, Scott, Wright, Cameron D, Kozono, David, Marcoux, Paul, Piotrowska, Zofia, Sequist, Lecia V, and Willers, Henning

Subjects
CANCER treatment, PATIENT safety, CISPLATIN, PEMETREXED, CLINICAL trials, TERMINATION of treatment, CHEMORADIOTHERAPY, DESCRIPTIVE statistics, OPERATIVE surgery, DRUG efficacy, COMBINED modality therapy, ONCOGENES, GENETIC mutation, LUNG cancer, CONSOLIDATION chemotherapy, PROGRESSION-free survival, CONFIDENCE intervals, DISEASE relapse, EPIDERMAL growth factor receptors, INDUCTION chemotherapy, AFATINIB, HISTOLOGY, SPECIALTY hospitals, OVERALL survival, PATIENT aftercare, EVALUATION, DISEASE risk factors
Abstract

Background The role of tyrosine kinase inhibitors (TKIs) in early-stage and metastatic oncogene-driven non–small cell lung cancer (NSCLC) is established, but it remains unknown how best to integrate TKIs with concurrent chemoradiotherapy (cCRT) in locally advanced disease. The phase 2 ASCENT trial assessed the efficacy and safety of afatinib and cCRT with or without surgery in locally advanced epidermal growth factor receptor (EGFR)-mutant NSCLC. Patients and Methods Adults ≥18 years with histologically confirmed stage III (AJCC 7th edition) NSCLC with activating EGFR mutations were enrolled at Mass General and Dana-Farber/Brigham Cancer Centers, Boston, Massachusetts. Patients received induction afatinib 40 mg daily for 2 months, then cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 IV every 3 weeks during RT (definitive or neoadjuvant dosing). Patients with resectable disease underwent surgery. All patients were offered consolidation afatinib for 2 years. The primary endpoint was the objective response rate (ORR) to induction TKI. Secondary endpoints were safety, conversion to operability, progression-free survival (PFS), and overall survival (OS). Analyses were performed on the intention-to-treat population. Results Nineteen patients (median age 56 years; 74% female) were enrolled. ORR to induction afatinib was 63%. Seventeen patients received cCRT; 2/9 previously unresectable became resectable. Ten underwent surgery; 6 had a major or complete pathological response. Thirteen received consolidation afatinib. With a median follow-up of 5.0 years, median PFS and OS were 2.6 (95% CI, 1.4-3.1) and 5.8 years (2.9-NR), respectively. Sixteen recurred or died; 6 recurrences were isolated to CNS. The median time to progression after stopping consolidation TKI was 2.9 months (95% CI, 1.1-7.2). Four developed grade 2 pneumonitis. There were no treatment-related deaths. Conclusion We explored the efficacy of combining TKI with cCRT in oncogene-driven NSCLC. Induction TKI did not compromise subsequent receipt of multimodality therapy. PFS was promising, but the prevalence of CNS-only recurrences and rapid progression after TKI discontinuation speak to unmet needs in measuring and eradicating micrometastatic disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer

Author

Sentana-Lledo, Daniel, primary, Viray, Hollis, additional, Piper-Vallillo, Andrew J., additional, Widick, Page, additional, Rangachari, Deepa, additional, Wilson, Jennifer L., additional, Gangadharan, Sidharta P., additional, Aronovitz, Joseph A., additional, Berman, Stuart M., additional, VanderLaan, Paul A., additional, and Costa, Daniel B., additional

Published
2022
Full Text
View/download PDF

7. Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19

Author

Klein, Isaac A., primary, Rosenberg, Shoshana M., additional, Reynolds, Kerry L., additional, Zubiri, Leyre, additional, Rosovsky, Rachel, additional, Piper-Vallillo, Andrew J., additional, Gao, Xin, additional, Boland, Genevieve, additional, Bardia, Aditya, additional, Gaither, Rachel, additional, Freeman, Hannah, additional, Kirkner, Gregory J., additional, Rhee, Chanu, additional, Klompas, Michael, additional, Baker, Meghan A., additional, Wadleigh, Martha, additional, Winer, Eric P., additional, Kotton, Camille N., additional, and Partridge, Ann H., additional

Published
2021
Full Text
View/download PDF

10. Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations

Author

Piper-Vallillo, Andrew J., primary, Mooradian, Meghan J., additional, Meador, Catherine B., additional, Yeap, Beow Y., additional, Peterson, Jennifer, additional, Sakhi, Mustafa, additional, Do, Andrew, additional, Zubiri, Leyre, additional, Stevens, Sara, additional, Vaughn, Jeanne, additional, Goodwin, Kelly, additional, Gavralidis, Alexander, additional, Willers, Henning, additional, Miller, Adam, additional, Farago, Anna, additional, Piotrowska, Zofia, additional, Lin, Jessica J., additional, Dagogo-Jack, Ibiayi, additional, Lennes, Inga T., additional, Sequist, Lecia V., additional, Temel, Jennifer S., additional, Heist, Rebecca S., additional, Digumarthy, Subba, additional, Reynolds, Kerry L., additional, and Gainor, Justin F., additional

Published
2021
Full Text
View/download PDF

16. Time to SARS-CoV-2 Clearance Among Patients with Cancer and COVID-19.

Author

Xu W, Piper-Vallillo AJ, Bindal P, Wischhusen J, Patel JM, Costa DB, and Peters MLB

Abstract

Question: What is the median time to clearance of SARS-CoV-2 among cancer patients according to currently used criteria?, Findings: In this single-institution retrospective cohort study, the median time to SARS-CoV-2 clearance was 50 days using the ASCO/CDC criteria of 2 negative RT-PCR assays >24 hours apart. Using alternative criteria of 1 negative RT-PCR assay (UK-NICE) or CDC clinical criteria (10 days after first positive RT-PCR and 3 days after last symptoms), median clearance times were 31 days and 13 days, respectively. Meaning: SARS-CoV-2 clearance times differ substantially depending on criteria used and may be prolonged in cancer patients.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results